A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.

Rodriguez, Pedro C; Torres-Moya, Roberto; Reyes, Gil; Molinero, Claudino; Prada, Dinorah; Lopez, Ana M; Hernandez, Isabel M; Hernandez, Maria V; Martinez, Jose P; Hernandez, Xochel; Casaco, Angel; Ramos, Mayra; Avila, Yisel; Barrese, Yinet; Montero, Enrique; Hernandez, Patricia

Rodriguez, Pedro C; Torres-Moya, Roberto; Reyes, Gil; Molinero, Claudino; Prada, Dinorah; Lopez, Ana M; Hernandez, Isabel M; Hernandez, Maria V; Martinez, Jose P; Hernandez, Xochel; Casaco, Angel; Ramos, Mayra; Avila, Yisel; Barrese, Yinet; Montero, Enrique; Hernandez, Patricia.

Afiliación

Rodriguez PC; Clinical Research Division, Center of Molecular Immunology, Havana, Cuba.
Torres-Moya R; National Service for Rheumatology, Havana, Cuba.
Reyes G; Rheumatology Service, Center of Surgical and Clinical Research, Havana, Cuba.
Molinero C; National Service for Rheumatology, Havana, Cuba.
Prada D; National Service for Rheumatology, Havana, Cuba.
Lopez AM; National Service for Rheumatology, Havana, Cuba.
Hernandez IM; National Service for Rheumatology, Havana, Cuba.
Hernandez MV; National Service for Rheumatology, Havana, Cuba.
Martinez JP; National Service for Rheumatology, Havana, Cuba.
Hernandez X; Clinical Research Division, Center of Molecular Immunology, Havana, Cuba.
Casaco A; Clinical Research Division, Center of Molecular Immunology, Havana, Cuba.
Ramos M; Clinical Research Division, Center of Molecular Immunology, Havana, Cuba.
Avila Y; National Coordinating Center of Clinical Trials, Havana, Cuba.
Barrese Y; National Coordinating Center of Clinical Trials, Havana, Cuba.
Montero E; Experimental Immunotherapy Department, Center of Molecular Immunology, Havana, Cuba.
Hernandez P; Clinical Research Division, Center of Molecular Immunology, Havana, Cuba.

Results Immunol ; 2: 204-11, 2012.

Article en En | MEDLINE | ID: mdl-24371585

Palabras clave

ACR, American College of Rheumatology; AE, adverse events; CD6; CRP, C reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, eritrosedimentation rate; Exploratory study; NSAIDs, nonsteroidal antiinflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor; Rheumatoid arthritis; SAE, serious adverse event.; T lymphocyte; iv, intravenous; mAbs, monoclonal antibodies

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Results Immunol Año: 2012 Tipo del documento: Article País de afiliación: Cuba

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google